The latest news:

• Curtana Pharmaceuticals Granted FDA Orphan Drug Designation for CT-179 for the Treatment of Gliomas         This targets Oligo2, which sounds like it might be a great target 
  



• STELLAR trial for Recurrent Anaplastic Astrocytoma         Orbus Therapeutics launched a new website for their clinical trial of oral Eflornithine (plus lomustine vs. lomustine alone).   Disclaimer: Orbus Therapeutics is a sponsor of the Musella Foundation.
  



• VBI Vaccines Announces FDA Acceptance of Investigational New Drug Application for VBI-1901 to Treat Glioblastoma Multiforme         This vaccine showed very good results in early trials!
  



• CHOP to lead new pediatric data resource center for research in childhood cancer, birth defects         This is the type of effort needed to make headway in the fight against cancer (and birth defects).   The Musella Foundation funded early work for this project which led to the big NIH grant which is making it a reality!
  



• Reengineering Immune System Cells to Fight Glioblastoma         This may lead to a breakthrough in the treatment of most cancers!
  



• OPTUNE OPEN HOUSE - NY Sept 9         This is for anyone thinking about using Optune.  It is a  lecture about the treatment, and there is a patient using the treatment that you can talk to.  It is for patients and caregivers.
  

BrainTumor Co-Payment Assistance Program Status:

• OPEN to new applicants